EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead

Vasileios Papaliagkas

International Journal of Molecular Sciences · 29.09.2025 · 26 (19) · 9529

DOI: 10.3390/ijms26199529 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.09.2025. Verfasst von Vasileios Papaliagkas. Beteiligte Einrichtung: Laboratory of Neurophysiology and Cognitive Neuroscience, Department of Biomedical Sciences, School of Health Sciences, International Hellenic Univer…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations. The FDA granted traditional approval to lecanemab in July 2023, and the European Medicines Agency approved it in late 2024 with specific genetic restrictions; meanwhile, donanemab received FDA approval in July 2024 and EMA marketing authorization just one month ago. These agents consistently clear cerebral amyloid and slow clinical decline modestly in early-stage, biomarker-confirmed Alzheimer’s disease (AD). On the other hand, they also create significant safety risks, including amyloid-related imaging abnormalities (ARIA) and substantial operational requirements for health systems that are already under pressure. Therefore, precise risk management based on APOE genotyping and the presence of cerebral amyloid angiopathy and cerebral microbleeds should be performed before therapy is initiated. The near-term agenda should prioritize the following areas of study: (1) biomarker-driven front-end triage (including emerging plasma assays); (2) ARIA-aware care pathways and shared decision making; (3) outcome-based coverage and rational pricing; (4) clinical trials that layer anti-amyloid therapy into combinatorial strategies targeting tau protein, neuroinflammation, and synaptic resilience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedHumansRisk ManagementApolipoproteins EClinical Trials as TopicPatient SelectionDecision Making, Shared

Stichwörter der Autor:innen

APOEARIAAlzheimer’s diseaseaducanumabamyloidbiomarkersdisease-modifying therapydonanemablecanemabvalue-based care

Substanzen

Amyloid beta-PeptideslecanemabAntibodies, Monoclonal, HumanizeddonanemabApoE protein, humanApolipoproteins E

Autor:innen und Institutionen

  • Laboratory of Neurophysiology and Cognitive Neuroscience, Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, 57001 Thessaloniki, Greece.

Zitieren

APA

Papaliagkas, V. (2025). Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead. International Journal of Molecular Sciences, 26(19), 9529. https://doi.org/10.3390/ijms26199529

Vancouver

Papaliagkas V. Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead. International Journal of Molecular Sciences. 2025;26(19):9529. doi:10.3390/ijms26199529

BibTeX
@article{Papaliagkas2025,
  author = {Papaliagkas, Vasileios},
  title = {Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {19},
  pages = {9529},
  doi = {10.3390/ijms26199529}
}
Kostenlos starten →